Helix Acquisition Corp. III

Last updated September 27, 2026

Organization details

Legal name
Helix Acquisition Corp. III
Ownership
Public
Status
Active
SIC code
6770 — Blank Checks
Jurisdiction of incorporation
Cayman Islands
Headquarters city
Boston
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
HLXC
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0002099656
EIN
98-1895727

Board of directors

Chief executives

Bihua Chen · Chairperson and CEO
Since January 2026

Board connections

3 of this board's directors also sit on 11 other boards.

Network of Helix Acquisition Corp. III's board connections BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology The... BlossomHill Therapeutics Inc. BlossomHill Therapeuti... AnaptysBio Inc. AnaptysBio Inc. Biomea Fusion Inc. Biomea Fusion Inc. Design Therapeutics Inc. Design Therapeutics In... Erasca Inc. Erasca Inc. First Tracks Biotherapeutics Inc. First Tracks Biotherap... Freenome Inc. Freenome Inc. NewAmsterdam Pharma Company N.V. NewAmsterdam Pharma Co... Spyre Therapeutics Inc. Spyre Therapeutics Inc... Xeris Biopharma Holdings Inc. Xeris Biopharma Holdin... Bihua Chen Bihua Chen John P. Schmid John P. Schmid Mark C. McKenna Mark C. McKenna Helix Acquisition Corp. II...
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jan 26, 2026 Bihua Chen Director, Officer (Chairperson and CEO), 10% owner Grant or award +497,500 $10.00 $4,975,000

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.